Engineering Amyloid Aggregation as a New Way to Eliminate Cancer Stem Cells by the Disruption of Iron Homeostasis
Source abstract
Abstract
Cancer stem cells (CSCs) play crucial roles in tumor initiation. Amyloid β (Aβ), which is associated with Alzheimer’s disease (AD), has been identified to induce cytotoxicity in tumor cells besides brain cells. Herein, we find that oligomeric Aβ1-42 and Aβ1-40 (OAβ1-42 and OAβ1-40) can repress the viability of breast CSCs. Intriguingly, OAβ1-42 and OAβ1-40 preferentially induce the growth arrest of breast CSCs by contrast with the bulk cancer cells. Further studies indicate that OAβ1-42 and OAβ1-40 disturb iron homeostasis, which results in iron accumulation in lysosomes. The iron in lysosomes then induces ROS production by Fenton reaction, leading to breast CSC death. In vivo experiments show that the tumorigenesis of breast CSCs pretreated with OAβ1-42 is inhibited. These results reveal that OAβ1-42 and OAβ1-40 are multifaceted players with the ability to eliminate CSCs. Our work may provide a new clue to better understand the biological functions of amyloid oligomers.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Epigenetics and DNA Methylation · Alzheimer's disease research and treatments · Cancer-related cognitive impairment studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Laboratory of Chemical Biology and State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin 130022, P. R. China
School of Applied Chemistry and Engineering, University of Science and Technology of China, Hefei, Anhui 230026, P. R. China
Funding
National Natural Science Foundation of China · Chinese Academy of Sciences · National Key R&D Program of China · Jilin Province Science and Technology Development Plan Project
References (64)
Show source-provided references
1. 10.1126/science.107299410.1126/science.1072994 ↗
2. 10.1038/nrneurol.2017.11110.1038/nrneurol.2017.111 ↗
3. 10.1016/j.cell.2012.02.04010.1016/j.cell.2012.02.040 ↗
4. 10.1126/sciadv.aao671810.1126/sciadv.aao6718 ↗
5. 10.1074/jbc.M20088720010.1074/jbc.M200887200 ↗
6. 10.1016/S0002-9440(10)63945-410.1016/S0002-9440(10)63945-4 ↗
7. 10.1073/pnas.130683211010.1073/pnas.1306832110 ↗
8. 10.1038/nrneurol.2015.11910.1038/nrneurol.2015.119 ↗
9. 10.1074/jbc.M40766820010.1074/jbc.M407668200 ↗
10. 10.1016/j.jalz.2008.10.00410.1016/j.jalz.2008.10.004 ↗
11. 10.1007/s12035-014-8854-y10.1007/s12035-014-8854-y ↗
12. 10.1007/s12640-016-9682-910.1007/s12640-016-9682-9 ↗
13. 10.1016/j.bbadis.2008.06.00310.1016/j.bbadis.2008.06.003 ↗
14. 10.1039/C4CC09390A10.1039/C4CC09390A ↗
15. 10.1021/jacs.7b0825910.1021/jacs.7b08259 ↗
16. 10.1016/j.bbamcr.2016.02.00810.1016/j.bbamcr.2016.02.008 ↗
17. 10.1023/B:AGEN.0000037335.17717.bf10.1023/B:AGEN.0000037335.17717.bf ↗
18. 10.1126/science.347.6219.22610.1126/science.347.6219.226 ↗
19. 10.1016/j.cell.2009.06.03410.1016/j.cell.2009.06.034 ↗
20. 10.1016/j.molonc.2010.06.00510.1016/j.molonc.2010.06.005 ↗
21. 10.1021/jacs.7b0749010.1021/jacs.7b07490 ↗
22. 10.1038/ng.12710.1038/ng.127 ↗
23. 10.1038/s41565-019-0406-110.1038/s41565-019-0406-1 ↗
24. 10.1021/acs.nanolett.7b0497610.1021/acs.nanolett.7b04976 ↗
25. 10.1158/0008-5472.CAN-05-062610.1158/0008-5472.CAN-05-0626 ↗
26. 10.1073/pnas.053029110010.1073/pnas.0530291100 ↗
27. 10.1186/bcr161010.1186/bcr1610 ↗
28. 10.1016/j.stem.2007.08.01410.1016/j.stem.2007.08.014 ↗
29. 10.1074/jbc.M50576320010.1074/jbc.M505763200 ↗
30. 10.1038/nsmb.179910.1038/nsmb.1799 ↗
31. 10.1021/ja511030s10.1021/ja511030s ↗
32. 10.3233/JAD-16034610.3233/JAD-160346 ↗
33. 10.1038/s41565-020-00793-010.1038/s41565-020-00793-0 ↗
34. 10.1073/pnas.92.6.198910.1073/pnas.92.6.1989 ↗
35. 10.3233/JAD-2012-12900110.3233/JAD-2012-129001 ↗
36. 10.1038/nature0773310.1038/nature07733 ↗
37. 10.1038/nature0966310.1038/nature09663 ↗
38. 10.1038/s41598-017-02227-910.1038/s41598-017-02227-9 ↗
39. 10.1016/j.redox.2017.10.01410.1016/j.redox.2017.10.014 ↗
40. 10.1038/nchem.277810.1038/nchem.2778 ↗
41. 10.1039/c2sc21649c10.1039/c2sc21649c ↗
42. 10.1128/MCB.01437-1010.1128/MCB.01437-10 ↗
43. 10.1021/bi300752r10.1021/bi300752r ↗
44. 10.7554/eLife.4819310.7554/eLife.48193 ↗
45. 10.1038/s41556-020-0461-810.1038/s41556-020-0461-8 ↗
46. 10.1038/nature1801410.1038/nature18014 ↗
47. 10.1016/j.celrep.2020.02.04910.1016/j.celrep.2020.02.049 ↗
48. 10.1038/ncomms698810.1038/ncomms6988 ↗
49. 10.1038/cdd.2013.20010.1038/cdd.2013.200 ↗
50. 10.1016/j.celrep.2017.11.09610.1016/j.celrep.2017.11.096 ↗
51. 10.1038/nrm210110.1038/nrm2101 ↗
52. 10.1039/C3CS60431D10.1039/C3CS60431D ↗
53. 10.1016/j.ntt.2010.12.00210.1016/j.ntt.2010.12.002 ↗
54. 10.1016/0891-5849(94)90239-910.1016/0891-5849(94)90239-9 ↗
55. 10.1021/ic201233b10.1021/ic201233b ↗
56. 10.1089/ars.2012.488510.1089/ars.2012.4885 ↗
57. 10.1016/S0891-5849(00)00319-110.1016/S0891-5849(00)00319-1 ↗
58. 10.1038/nrc349510.1038/nrc3495 ↗
59. 10.3233/JAD-16097710.3233/JAD-160977 ↗
60. 10.1038/nrn346410.1038/nrn3464 ↗
61. 10.1016/j.jalz.2016.11.00210.1016/j.jalz.2016.11.002 ↗
62. 10.1098/rsif.2013.000610.1098/rsif.2013.0006 ↗
63. 10.1016/j.stem.2018.12.00910.1016/j.stem.2018.12.009 ↗
64. 10.1039/C9SC02651G10.1039/C9SC02651G ↗